Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Afd Pharmacoepi & Clinical Pharmacology"'
Autor:
Li, Wenlong, Sparidans, Rolf W, Martins, Margarida L F, El-Lari, Mujtaba, Lebre, Maria C, van Tellingen, Olaf, Beijnen, Jos H, Schinkel, Alfred H, Afd Pharmacoepi & Clinical Pharmacology, Afd Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Pharmacology
Publikováno v:
Molecular Cancer Therapeutics, 20(6), 1173. American Association for Cancer Research Inc.
Selitrectinib (BAY2731954; LOXO-195) is a promising oral tropomyosin receptor kinase (TRK) inhibitor currently in phase I/II clinical trials for the treatment of histology-agnostic cancers positive for TRK fusions. With therapeutic resistance eventua
Autor:
Ebbelaar, Chiel F, Jansen, Anne M L, Bloem, Lourens T, Blokx, Willeke A M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Virchows Archiv
Virchows Archiv, 479(4), 773. Springer Verlag
Virchows Archiv, 479(4), 773. Springer Verlag
Cutaneous intermediate melanocytic neoplasms with ambiguous histopathological features are diagnostically challenging. Ancillary cytogenetic techniques to detect genome-wide copy number variations (CNVs) might provide a valuable tool to allow accurat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b9b0628358b038cf240bed86e209eff
https://dspace.library.uu.nl/handle/1874/413903
https://dspace.library.uu.nl/handle/1874/413903
Autor:
Ismail, R. K., Schramel, F. M.N.H., van Dartel, M., Hilarius, D. L., de Boer, A., Wouters, M. W.J.M., Smit, H. J.M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Lung Cancer, 149, 68. Elsevier Ireland Ltd.
Lung Cancer, 149, 68-77. ELSEVIER IRELAND LTD
Lung Cancer, 149, 68-77. ELSEVIER IRELAND LTD
Objectives This study describes the initiation of the Dutch Lung Cancer Audit for Lung Oncology (DLCA-L) and reports the first results of three years of clinical auditing. Methods The initiation, dataset, and data quality of the DLCA-L are described.
Autor:
Pei, J, Schuldt, M, Nagyova, E, Gu, Z, El Bouhaddani, S, Yiangou, L, Jansen, M, Calis, J J A, Dorsch, L M, Blok, C Snijders, van den Dungen, N A M, Lansu, N, Boukens, B J, Efimov, I R, Michels, M, Verhaar, M C, de Weger, R, Vink, A, van Steenbeek, F G, Baas, A F, Davis, R P, Uh, H W, Kuster, D W D, Cheng, C, Mokry, M, van der Velden, J, Asselbergs, F W, Harakalova, M, Afd Pharmacoepi & Clinical Pharmacology, Interne geneeskunde GD, dCSCA AVR, Sub Inorganic Chemistry and Catalysis, LS Vertaalwetenschap, CS_Genetics
Publikováno v:
Clinical Epigenetics, 13(1):61. BioMed Central Ltd.
Clinical epigenetics, 13(1):61. Springer Verlag
Pei, J, Schuldt, M, Nagyova, E, Gu, Z, el Bouhaddani, S, Yiangou, L, Jansen, M, Calis, J J A, Dorsch, L M, Blok, C S, van den Dungen, N A M, Lansu, N, Boukens, B J, Efimov, I R, Michels, M, Verhaar, M C, de Weger, R, Vink, A, van Steenbeek, F G, Baas, A F, Davis, R P, Uh, H W, Kuster, D W D, Cheng, C, Mokry, M, van der Velden, J, Asselbergs, F W & Harakalova, M 2021, ' Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations ', Clinical epigenetics, vol. 13, no. 1, 61 . https://doi.org/10.1186/s13148-021-01043-3
Clinical Epigenetics
Clinical Epigenetics, 13(1), 1. BioMed Central
Clinical Epigenetics, 13(1). BMC
Clinical epigenetics, 13(1):61. Springer Verlag
Pei, J, Schuldt, M, Nagyova, E, Gu, Z, el Bouhaddani, S, Yiangou, L, Jansen, M, Calis, J J A, Dorsch, L M, Blok, C S, van den Dungen, N A M, Lansu, N, Boukens, B J, Efimov, I R, Michels, M, Verhaar, M C, de Weger, R, Vink, A, van Steenbeek, F G, Baas, A F, Davis, R P, Uh, H W, Kuster, D W D, Cheng, C, Mokry, M, van der Velden, J, Asselbergs, F W & Harakalova, M 2021, ' Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations ', Clinical epigenetics, vol. 13, no. 1, 61 . https://doi.org/10.1186/s13148-021-01043-3
Clinical Epigenetics
Clinical Epigenetics, 13(1), 1. BioMed Central
Clinical Epigenetics, 13(1). BMC
Background Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the cardiac muscle, frequently caused by mutations in MYBPC3. However, little is known about the upstream pathways and key regulators causing the disease. Therefore, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48513be4255f80671f2b51e974fc2314
https://pure.eur.nl/en/publications/a2126346-ea8a-4e36-ba69-e93fb8de9a58
https://pure.eur.nl/en/publications/a2126346-ea8a-4e36-ba69-e93fb8de9a58
Autor:
Alsamil, Ali M, Giezen, Thijs J, Egberts, Toine C, Leufkens, Hubert G, Gardarsdottir, Helga, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Pharmaceuticals
Volume 14
Issue 3
Pharmaceuticals, Vol 14, Iss 189, p 189 (2021)
Pharmaceuticals (Basel, Switzerland), 14(3), 1. MDPI AG
Volume 14
Issue 3
Pharmaceuticals, Vol 14, Iss 189, p 189 (2021)
Pharmaceuticals (Basel, Switzerland), 14(3), 1. MDPI AG
Regulatory approval of biosimilars predominantly relies on biosimilarity assessments of quality attributes (QAs), particularly the potentially critical QAs (pCQAs) that may affect the clinical profile. However, a limited understanding exists concerni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9dfa195948044b2dc06552dfd653e5
https://dspace.library.uu.nl/handle/1874/411691
https://dspace.library.uu.nl/handle/1874/411691
Autor:
Abedian, Shifteh, Abbasi, Ali, de Boer, Anthonius, Stricker, Bruno H, Bakker, Stephan J L, van der Harst, Pim, Sedaghat, Sanaz, Darvishian, Maryam, Ikram, M Arfan, Navis, Gerjan, Dehghan, Abbas, Pen, Ido, Stolk, Ronald P, Snieder, Harold, Klungel, Olaf H, Souverein, Patrick, Alizadeh, Behrooz Z, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Scientific Reports
Scientific Reports, 11(1). NLM (Medline)
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports, 11(1):2794. Nature Publishing Group
Scientific Reports, 11(1). NLM (Medline)
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports, 11(1):2794. Nature Publishing Group
Underlying genetic determinants contribute to developing type 2 diabetes (T2D) future diseases. The present study aimed to identify which genetic variants are associated with the incident of the major T2D co-morbid disease. First, we conducted a disc
Autor:
van Bussel, Mark T J, Beijnen, Jos H, Brandsma, Dieta, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
BMC Cancer
BMC Cancer, 19(1). BioMed Central
BMC Cancer
BMC Cancer, 19(1). BioMed Central
Background Recently, two phase II trials showed intracranial activity of the immune checkpoint inhibitors nivolumab and ipilimumab in patients with melanoma brain metastases. However, it is generally assumed that large molecules like monoclonal antib
Autor:
van Berlo – van de Laar, I. R.F., Brummelhuis, W. J., Imholz, A. L.T., Schellens, J. H., Huitema, A. D.R., Jansman, F. G.A., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics, 43(4), 574. Blackwell Publishing Ltd
Journal of Clinical Pharmacy and Therapeutics, 43(4), 574. Wiley-Blackwell
Journal of Clinical Pharmacy and Therapeutics, 43(4), 574-577. Blackwell Publishing Ltd
Journal of Clinical Pharmacy and Therapeutics, 43(4), 574. Wiley-Blackwell
Journal of Clinical Pharmacy and Therapeutics, 43(4), 574-577. Blackwell Publishing Ltd
WHAT IS KNOWN AND OBJECTIVE: Oxaliplatin in combination with fluorouracil and folinic acid is one of the preferred chemotherapeutic options in the treatment of metastatic rectum cancer. However, oxaliplatin is contraindicated in patients with a creat
Autor:
Klein, Kevin, Stolk, Pieter, De Bruin, Marie Louise, Leufkens, Hubert, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Klein, K, Stolk, P, De Bruin, M L & Leufkens, H 2021, ' Regulatory density as a means to refine current regulatory approaches for increasingly complex medicines ', Drug Discovery Today, vol. 26, no. 10, pp. 2221-2225 . https://doi.org/10.1016/j.drudis.2021.04.005
Drug Discovery Today, 26(10), 2221. Elsevier Ltd
Drug Discovery Today, 26(10), 2221. Elsevier Ltd
The continuous scientific, societal, and technological advancements have shifted drug development toward increasingly complex and ever more targeted treatments. This creates new and unprecedented challenges for global regulatory systems. To address t
Autor:
ten Ham, Renske M.T., Nievaart, Julianne C., Hoekman, Jarno, Cooper, Rachel S., Frederix, Geert W.J., Leufkens, Hubert G.M., Klungel, Olaf H., Ovelgönne, Hans, Hoefnagel, Marcel H.N., Turner, Marc L., Mountford, Joanne C., Innovation Studies, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Innovation and Sustainability
Publikováno v:
Cytotherapy, 23(8), 730. Elsevier bedrijfsinformatie b.v.
Background aims Cell-based therapies (CBTs) provide opportunities to treat rare and high-burden diseases. Manufacturing development of these innovative products is said to be complex and costly. However, little research is available providing insight
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eea0f429ccc4994d43dac7335e81461
https://dspace.library.uu.nl/handle/1874/411748
https://dspace.library.uu.nl/handle/1874/411748